Cooper Companies
COO · NasdaqOphthalmic Goods · Fiscal year ends Oct 31
Cooper Companies reported revenue of $4.1B in the fiscal year ended Oct 2025, up 5.1% from the year before. Operating income was $683M, an operating margin of 16.7%, and net income was $375M. Operating cash flow of $796M less capital expenditure of $362M left free cash flow of $434M. Net debt was $2.4B.
Last 5 fiscal years
Revenue and net income
Income statement
| Fiscal year | Oct 2021 | Oct 2022 | Oct 2023 | Oct 2024 | Oct 2025 |
|---|---|---|---|---|---|
| Revenue | $2.9B | $3.3B | $3.6B | $3.9B | $4.1B |
| Cost of revenue | $967M | $1.2B | $1.2B | $1.3B | $1.4B |
| Gross profit | $2B | $2.1B | $2.4B | $2.6B | $2.7B |
| Research & development | $93M | $110M | $137M | $155M | $172M |
| Selling, general & admin | $1.2B | $1.3B | $1.5B | $1.5B | $1.6B |
| Operating income | $506M | $508M | $533M | $706M | $683M |
| Interest expense | $23M | $57M | $105M | $114M | $100M |
| Pre-tax income | $492M | $475M | $413M | $582M | $567M |
| Income tax | −$2.5B | $90M | $119M | $190M | $192M |
| Net income | $2.9B | $386M | $294M | $392M | $375M |
| Diluted EPS | 59.16 | 1.94 | 1.48 | 1.96 | 1.87 |
| Diluted shares | 50M | 199M | 199M | 200M | 200M |
Balance sheet
| Fiscal year | Oct 2021 | Oct 2022 | Oct 2023 | Oct 2024 | Oct 2025 |
|---|---|---|---|---|---|
| Cash & equivalents | $96M | $138M | $121M | $108M | $111M |
| Receivables | $515M | $558M | $610M | $717M | $829M |
| Inventory | $586M | $629M | $736M | $803M | $846M |
| Current assets | $1.5B | $1.5B | $1.7B | $2B | $2.1B |
| Net PP&E | $1.3B | $1.4B | $1.6B | $1.9B | $2.1B |
| Goodwill | $2.6B | $3.6B | $3.6B | $3.8B | $3.9B |
| Total assets | $9.6B | $11.5B | $11.7B | $12.3B | $12.4B |
| Payables | $161M | $249M | $262M | $261M | $300M |
| Deferred revenue | $19M | $94M | $124M | $130M | $128M |
| Current liabilities | $732M | $1.3B | $969M | $1B | $1.1B |
| Short-term debt | $83M | $413M | $45M | $33M | $48M |
| Long-term debt | $1.4B | $2.3B | $2.5B | $2.5B | $2.5B |
| Total liabilities | $2.7B | $4.3B | $4.1B | $4.2B | $4.2B |
| Shareholders' equity | $6.9B | $7.2B | $7.6B | $8.1B | $8.2B |
Cash flow
| Fiscal year | Oct 2021 | Oct 2022 | Oct 2023 | Oct 2024 | Oct 2025 |
|---|---|---|---|---|---|
| Operating cash flow | $739M | $692M | $608M | $709M | $796M |
| Capital expenditure | $214M | $242M | $393M | $421M | $362M |
| Free cash flow | $524M | $450M | $215M | $288M | $434M |
| Depreciation & amortisation | $309M | $346M | $368M | $375M | $377M |
| Stock-based compensation | $44M | $54M | $62M | $75M | $71M |
| Share buybacks | $25M | $79M | $0 | $0 | $290M |
| Dividends paid | $3M | $3M | $3M | $0 | $0 |
| Dividend per share | 0.03 | 0.01 | 0.01 | – | – |
Key ratios
| Fiscal year | Oct 2021 | Oct 2022 | Oct 2023 | Oct 2024 | Oct 2025 |
|---|---|---|---|---|---|
| Revenue growth (YoY) | – | 13.2% | 8.6% | 8.4% | 5.1% |
| Operating income growth (YoY) | – | 0.4% | 5.0% | 32.4% | −3.2% |
| EPS growth (YoY) | – | −96.7% | −23.7% | 32.4% | −4.6% |
| Gross margin | 66.9% | 64.7% | 65.6% | 66.6% | 65.5% |
| Operating margin | 17.3% | 15.3% | 14.8% | 18.1% | 16.7% |
| Net margin | 100.8% | 11.7% | 8.2% | 10.1% | 9.2% |
| Return on equityBlank when equity is negative | 42.4% | 5.4% | 3.9% | 4.9% | 4.6% |
| ROCEEBIT ÷ (assets − current liabilities) | 5.7% | 5.0% | 5.0% | 6.2% | 6.1% |
| Free cash flow margin | 17.9% | 13.6% | 6.0% | 7.4% | 10.6% |
| Cash conversion (CFO ÷ net income) | 0.25x | 1.79x | 2.06x | 1.81x | 2.12x |
| Receivable days | 64 | 62 | 62 | 67 | 74 |
| Inventory days | 221 | 196 | 217 | 225 | 219 |
| Payable days | 61 | 78 | 77 | 73 | 78 |
| Interest cover | 21.9x | 8.86x | 5.06x | 6.17x | 6.83x |
| Debt ÷ equity | 0.21x | 0.38x | 0.34x | 0.32x | 0.30x |
| Net debtDebt − cash & equivalents; excludes investments; negative = net cash | $1.4B | $2.6B | $2.4B | $2.5B | $2.4B |
| Current ratio | 2.00x | 1.20x | 1.76x | 1.91x | 1.89x |
Recent filings
More in Ophthalmic Goods
Standardised figures from the company's XBRL filings with the SEC (10-K, 10-Q). Line items follow US GAAP tags, so a company's own statement layout may differ and some lines show “–” where the company does not report that item. Ratios are calculated from these figures. For education only; not investment advice or a recommendation.